Vericel Corp. (VCEL)
38.41
+1.03
(+2.76%)
USD |
NASDAQ |
Jun 11, 13:14
Vericel Price to Book Value : 5.500 for June 11, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 5.353 |
| June 09, 2026 | 5.302 |
| June 08, 2026 | 5.122 |
| June 05, 2026 | 5.198 |
| June 04, 2026 | 5.111 |
| June 03, 2026 | 4.974 |
| June 02, 2026 | 4.933 |
| June 01, 2026 | 4.700 |
| May 29, 2026 | 4.773 |
| May 28, 2026 | 4.903 |
| May 27, 2026 | 4.913 |
| May 26, 2026 | 5.013 |
| May 22, 2026 | 4.979 |
| May 21, 2026 | 5.039 |
| May 20, 2026 | 5.075 |
| May 19, 2026 | 4.944 |
| May 18, 2026 | 4.999 |
| May 15, 2026 | 4.735 |
| May 14, 2026 | 4.751 |
| May 13, 2026 | 4.708 |
| May 12, 2026 | 4.722 |
| May 11, 2026 | 4.719 |
| May 08, 2026 | 4.797 |
| May 07, 2026 | 5.036 |
| May 06, 2026 | 5.273 |
| Date | Value |
|---|---|
| May 05, 2026 | 5.277 |
| May 04, 2026 | 5.231 |
| May 01, 2026 | 5.099 |
| April 30, 2026 | 4.979 |
| April 29, 2026 | 4.787 |
| April 28, 2026 | 5.105 |
| April 27, 2026 | 5.287 |
| April 24, 2026 | 5.103 |
| April 23, 2026 | 4.926 |
| April 22, 2026 | 4.922 |
| April 21, 2026 | 4.821 |
| April 20, 2026 | 5.128 |
| April 17, 2026 | 5.109 |
| April 16, 2026 | 4.836 |
| April 15, 2026 | 5.065 |
| April 14, 2026 | 5.032 |
| April 13, 2026 | 4.932 |
| April 10, 2026 | 4.826 |
| April 09, 2026 | 4.810 |
| April 08, 2026 | 4.873 |
| April 07, 2026 | 4.773 |
| April 06, 2026 | 4.88 |
| April 02, 2026 | 4.889 |
| April 01, 2026 | 4.662 |
| March 31, 2026 | 4.606 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Marker Therapeutics, Inc. | 1.644 |
| Krystal Biotech, Inc. | 7.403 |
| TG Therapeutics, Inc. | 12.50 |
| Gyre Therapeutics, Inc. | 5.518 |
| ACADIA Pharmaceuticals, Inc. | 2.925 |
Price to Book Value Related Metrics
| PE Ratio | 93.89 |
| PS Ratio | 6.743 |
| PEG Ratio | 0.1001 |
| Price to Free Cash Flow | 41.48 |
| Price | 38.41 |
| Earnings Yield | 1.07% |
| Market Cap | 1.959B |
| PEGY Ratio | 0.1001 |
| Operating PE Ratio | 124.88 |
| Normalized PE Ratio | 93.91 |